Morse Faria, O. Ismaiel, James Waltrip, Thomas Mariannino, Moucun Yuan, W. Mylott, V. Roongta, Jim X. Shen, Pathanjali Kadiya
{"title":"LC-MS/MS法定量测定人血浆中丹那霉素及其活性代谢物:方法验证及克服APCI源隐匿现象","authors":"Morse Faria, O. Ismaiel, James Waltrip, Thomas Mariannino, Moucun Yuan, W. Mylott, V. Roongta, Jim X. Shen, Pathanjali Kadiya","doi":"10.17145/jab.20.015","DOIUrl":null,"url":null,"abstract":"RESULTS: A sensitive method was developed and validated for the measurement of tanespimycin and its active 17-AG in human plasma using tanespimycin -C3, 15N as an internal standard. The assay was validated over the concentration range of 10.0 to 2500 ng/mL for tanespimycin and 5.00 to 1250 ng/mL for 17-AG. During method development, an internal standard variability due to an in-source reduction of the quinone moiety during ionization was observed. The in-source reduction was mitigated by selection of appropriate mobile phases, internal standard concentration, injection volume, source temperature, and continuous maintenance of the source between runs.","PeriodicalId":15014,"journal":{"name":"Journal of Applied Bioanalysis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LC-MS/MS Method for the Quantitative Determination of Tanespimycin and its Active Metabolite in Human Plasma: Method Validation and Overcoming an Insidious APCI Source Phenomenon\",\"authors\":\"Morse Faria, O. Ismaiel, James Waltrip, Thomas Mariannino, Moucun Yuan, W. Mylott, V. Roongta, Jim X. Shen, Pathanjali Kadiya\",\"doi\":\"10.17145/jab.20.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"RESULTS: A sensitive method was developed and validated for the measurement of tanespimycin and its active 17-AG in human plasma using tanespimycin -C3, 15N as an internal standard. The assay was validated over the concentration range of 10.0 to 2500 ng/mL for tanespimycin and 5.00 to 1250 ng/mL for 17-AG. During method development, an internal standard variability due to an in-source reduction of the quinone moiety during ionization was observed. The in-source reduction was mitigated by selection of appropriate mobile phases, internal standard concentration, injection volume, source temperature, and continuous maintenance of the source between runs.\",\"PeriodicalId\":15014,\"journal\":{\"name\":\"Journal of Applied Bioanalysis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Applied Bioanalysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17145/jab.20.015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Bioanalysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17145/jab.20.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LC-MS/MS Method for the Quantitative Determination of Tanespimycin and its Active Metabolite in Human Plasma: Method Validation and Overcoming an Insidious APCI Source Phenomenon
RESULTS: A sensitive method was developed and validated for the measurement of tanespimycin and its active 17-AG in human plasma using tanespimycin -C3, 15N as an internal standard. The assay was validated over the concentration range of 10.0 to 2500 ng/mL for tanespimycin and 5.00 to 1250 ng/mL for 17-AG. During method development, an internal standard variability due to an in-source reduction of the quinone moiety during ionization was observed. The in-source reduction was mitigated by selection of appropriate mobile phases, internal standard concentration, injection volume, source temperature, and continuous maintenance of the source between runs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
